Jasper Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesJan 9 10:35 ET · Ratings

A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $80

Moomoo NewsJan 9 08:00 ET · Ratings

RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk

MT NewswiresJan 9 06:18 ET · Ratings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaJan 8 16:06 ET

Promising Efficacy and Safety of Jasper Therapeutics' Briquilimab Boosts Buy Rating

TipRanksJan 8 15:35 ET · Ratings

Jasper Therapeutics Price Target Lowered to $64 From $90 at BTIG

TipRanksJan 8 15:20 ET